Given the elevated METTL5 expression in clinically “cold” tumors and poor responders, selective inhibition of METTL5 may provide a rational approach to overcome tumor immune evasion and broaden the efficacy of immunotherapy across otherwise refractory cancers. This evidence concerns the gene METTL5 and neoplasm.